A critical review of methotrexate clinical interactions: role of transporters

Jafari, Fatemeh; Arasteh, Omid; Hosseinjani, Hesamoddin; Allahyari, Abolghasem; Azimi, Sajad Ataei; Askari, Vahid Reza

doi:10.1080/17425255.2023.2193325

Cited by 1 publication

(2 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have shown that drug-MET interactions play important role in increasing MET concentrations by inhibiting the transporters that are responsible for renal excretion of MET. 9 Nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to have interaction with MET leading to decreased elimination. Nevertheless, MET is prescribed in combination with NSAIDs.…”

Section: ■ Introductionmentioning

confidence: 99%

“…Different uptake and efflux transporters are thought to be associated with the mechanism of drug–drug interactions in MET clearance. Many studies have shown that drug-MET interactions play important role in increasing MET concentrations by inhibiting the transporters that are responsible for renal excretion of MET . Nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to have interaction with MET leading to decreased elimination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methotrexate-Loaded Surface-Modified Solid Lipid Nanoparticles Targeting Cancer Expressing COX-2 Enzyme

Patra,

Dey,

Kar

et al. 2024

Langmuir

View full text Add to dashboard Cite

Cancer is a major public health problem worldwide, and it is the second leading cause of death of humans in the world. The present study has been directed toward the preparation of methotrexateloaded surface-modified solid lipid nanoparticles (SLNs) for potential use as a chemotherapeutic formulation for cancer therapy. A lipid (C 14 -AAP) derived from myristic acid (C 14 H 30 O 2 ) and acetaminophen (AAP) was employed as a targeting ligand for human breast and lung cancer cells that overexpress the cyclooxygenases-2 (COX-2) enzyme. The SLNs consisting of stearic acid and C 14 -AAP were characterized by several methods, including dynamic light scattering (DLS), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), ultraviolet−visible (UV−vis) spectroscopy, high-resolution transmission electron microscopy (HRTEM), and field emission scanning electron microscopy (FESEM) techniques. An in vitro cell cytotoxicity study was done by carrying out an MTT assay and flow cytometry study in the human breast cancer (MCF7) and human lung cancer cell line (A549). The expression level of COX-2 enzyme in MCF7 and A549 cell lines was examined by reverse transcription polymerase chain reaction (RT-PCR). A high level of COX-2 expression was observed in both cell lines. In vitro cell cytotoxicity study in MC7 and A549 cell lines showed the surface-modified, methotrexate-loaded SLN is more effective in cell killing and induction of apoptotic death in both the cell lines than free methotrexate in MTT, flow cytometry, clonogenic assay, and Western blot studies. The surface-modified SLN was radiolabeled with 99m Tc with %RCP greater than 95%. In vivo biodistribution study of the 99m Tc-labeled SLN in melanoma tumor-bearing C57BL6 mice showed moderate tumor uptake of the radiotracer at 3 h post injection. The SPECT/CT image aligns with the biodistribution results. This study shows that AAP-modified SLNs could be a potential chemotherapeutic formulation for cancer therapy.

show abstract

Section: ■ Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%